Publication | Open Access

Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis

Second-line TreatmentHepatologyRegorafenib Versus CabozantinbMedicinePharmacologyPathologyPharmacotherapyLiver CancerCancer TreatmentOncologyUnresectable Hepatocellular CarcinomaHepatocellular CarcinomaCancer Research